<DOC>
	<DOCNO>NCT01569464</DOCNO>
	<brief_summary>The purpose study show Rotigotine improve Restless Legs Syndrome ( RLS ) symptoms subject moderate severe RLS day evening .</brief_summary>
	<brief_title>Rotigotine Effect All-day Functioning Quality Life Subjects With Moderate Severe Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>An Institutional Review Board ( IRB ) approve write Informed Consent Form ( ICF ) sign date subject Subject understand investigational nature study willing able comply study requirement . Subject willing accept he/she might treat Placebo Treatment Period Subject male female , ≥ 18 ≤ 75 year age Subject able apply/remove study patch correctly Subject meet diagnosis Idiopathic Restless Legs Syndrome ( IRLS ) base 4 essential clinical feature accord International Restless Legs Syndrome Study Group ( Allen et al , 2003 ) : 1 . An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg . ( The urge move present without uncomfortable sensation . Arms body part also affect ) 2 . The urge move unpleasant sensation begin worsen period rest inactivity lie sit 3 . The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue 4 . The urge move unpleasant sensation worse even night day occur even night . ( When symptom severe , worsen night may noticeable must previously present ) At Baseline ( Visit 2 ) , subject score ≥ 11 RLSDiagnostic Index ( RLSDI ) ( Benes Kohnen , 2009 ) Subject must attempt 4 Suggested Immobilization Test ( SIT ) assessment Baseline ( Visit 2 ) At Baseline ( Visit 2 ) subject average Multiple Suggested Immobilization Test Discomfort Scale ( mSITDS ) least 1.5 course Multiple Suggested Immobilization Test ( SIT ) The subject 's Body Mass Index ≥ 18 kg/m^2 ≤ 35 kg/m^2 Visit 1 At Baseline ( Visit 2 ) , subject score ≥ 15 International Restless Legs Scale ( IRLS ) ( indicate moderate severe RLS ) At Baseline ( Visit 2 ) , subject score `` Severe '' `` Very Severe '' Item 8 IRLS ( Item 8 : When RLS symptom severe average ? ) At Baseline ( Visit 2 ) , subject score ≥ 4 point Clinical Global Impression ( CGI ) Item 1 assessment ( indicate moderately ill ) Subject previously participate study receive previous treatment Rotigotine Subject participate another study investigational medicinal product ( IMP ) medical device within last 30 day prior Visit 1 , currently participate another study IMP medical device Subject secondary RLS ( eg , due Renal Insufficiency [ Uremia ] , Iron Deficiency Anemia Rheumatoid Arthritis ) Subject Ferritin value ≤ 18 µg/L within last 3 month prior Baseline ( Visit 2 ) Subject RLS associate previous concomitant therapy Dopamine Receptor Antagonists , Butyrophenones , Metoclopramide , Atypical Antipsychotics ( eg , Olanzapine ) , Tri TetraCyclic Antidepressants , Mianserine , Lithium H2Blockers ( eg , Cimetidine ) , due withdrawal drug Anticonvulsants , Benzodiazepines , Barbiturates , Hypnotics Subject evidence Impulse Control Disorder accord Modified Minnesota Impulsive Disorders Interview ( mMIDI ) Screening ( Visit 1 ) Subject history sleep disturbance , Sleep Apnea Syndrome ( include Obstructive Sleep Apnea ) , Narcolepsy , Sleep Attacks/Sudden Onset Sleep , Myoclonus Epilepsy either observe Polysomnography ( PSG ) ( local PSG evaluation ) evidence subject history Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( 'Yes ' ) either Question 4 Question 5 Columbia Suicide Severity Rating Scale ( CSSRS ) Screening ( Visit 1 ) Subject uncontrolled Hypertension accord judgment investigator Subject additional clinically relevant concomitant disease , Attention Deficit Hyperactivity Disorder , Polyneuropathy , Claudication , Varicosis , Muscle Fasciculation , painful leg move toe , Radiculopathy Subject central nervous system disease , Parkinson 's Disease , Dementia , Progressive Supranuclear Paresis , Multisystem Atrophy , Huntington 's Chorea , Amyotrophic Lateral Sclerosis , Alzheimer 's Disease Subject prior history psychotic episode Subject history chronic alcohol drug abuse within last 12 month prior Visit 1 Subject medical psychiatric condition , opinion investigator , could jeopardize would compromise subject 's well ability participate study Subject clinically relevant Venous Arterial Peripheral Vascular Disease Subject malignant Neoplastic Disease require therapy within 12 month prior Screening ( Visit 1 ) Subject currently receive treatment follow drug class : Neuroleptics , Hypnotics , Antidepressants , Anxiolytic Drugs , Anticonvulsive Therapy , Budipine , Dopamine Antagonist Antiemetics ( except Domperidone ) , Opioids , Benzodiazepines , Monoamine Oxidase ( MAO ) Inhibitors , CatecholOMethyltransferase ( COMT ) Inhibitors , Sedative Antihistamines , Psychostimulates , Amphetamines . If subject receive therapy , Washout Period least 7 day prior Baseline ( Visit 2 ) require start treatment study Subject pregnant , nursing , woman childbearing potential surgically sterile , 2 year postmenopausal , consistently use 2 combine medically acceptable method contraception , include least 1 barrier method , unless sexually abstinent Subject shift worker perform continuous nondiseaserelated life condition allow regular sleep night At Screening Visit ( Visit 1 ) Baseline Visit ( Visit 2 ) , subject Symptomatic Orthostatic Hypotension decrease Blood Pressure ( BP ) supine stand position ≥ 20 mmHg systolic BP ≥ 10 mmHg diastolic BP take 5minute supine 1 and/or 3minute stand measurement Visit 1 Visit 2 Subject treat Dopamine Agonists within period 7 day prior Baseline ( Visit 2 ) LDopa within 3 day prior Baseline ( Visit 2 ) Subject know history indicate intolerability prior Dopaminergic therapy ( pretreated ) previously treat Dopaminergic agent Subject know hypersensitivity component study medication , history significant skin hypersensitivity adhesive , know hypersensitivity transdermal medication , unresolved contact Dermatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>Neupro®</keyword>
</DOC>